Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL+ human leukemic cells: Association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition

Blood

Volumn 97, Issue 9, 2001, Pages 2846-2853

  Donato, Nicholas J ^a   Wu, Ji Y ^a   Zhang, Ling ^a   Kantarjian, Hagop ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0035353191     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2846     Document Type: Article

References (55)

1. Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell. 1991;64:347-350.
2. Calabretta B, Skorski T. Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Crit Rev Eukaryot Gene Expr. 1997;7:117-124.
3. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
4. Mitani K. Leukemogenesis by the chromosomal translocations. Leukemia. 1997;3:294-296.
5. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-214.
6. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
7. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
8. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806-809.
9. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta. 1997;1333:F201-F216.
10. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
11. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multi-potential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A. 2000;97:1737-1742.
12. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
13. Malgorzata N-S, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999;189:1229-1242.
14. Neshat MS, RaitanoAB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20:1179-1186.
15. Pendergast AM, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol. 1993;13:1728-1736.
16. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161-171.
17. Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood. 1994;83:1575-1585.
18. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT-5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000;95:2118-2125.
19. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT-5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94:1108-1112.
20. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 1996;10:1724-1730.
21. Carroll M, Ohno-Jones S, Tamura S, et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
22. Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
23. Beran M, Cao X, Estrov Z, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661-1672.
24. Donato NJ, Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J Biol Chem. 1998;273:5067-5072.
25. Donato NJ, Yan D-H, Hung M-C, Rosenblum MG. EGF receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. Cell Growth Differ. 1993;4:411-419.
26. Nishikawa K, Pandita T, Hittelman W, Newman RA, Rosenblum MG, Donato NJ. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with increased sensitivity to cis platin: evidence of a role for epidermal growth factor receptor. Cancer Res. 1992;52:4758-4765.
27. Perez M, Haschke B, Donato NJ. Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: evidence for their dephosphorylation of epidermal growth factor receptor. Oncogene. 1998;17:2133-2144.
28. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 1998;16:1383-1390.
29. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977-984.
30. LaMontagne KR Jr, Flint AJ, Franza BR Jr, Pandergast AM, Tonks NK. Protein tyrosine phosphatase 1B antagonizes signaling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol Cell Biol. 1998;18:2965-2975.
31. Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol. 2000;47:113-174.
32. Dumon S, Santos SC, Debierre-Grockiego F, et al. IL-3 dependent regulation of Bcl-xL gene expression by Stat-5 in a bone marrow derived cell line. Oncogene. 1999;18:4191-4199.
33. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy: signal transducer an activator of transcription. Curr Opin Oncol. 1999;11:490-496.
34. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 1998;5:79-85,
35. Santos RSC, Mayeux DP, Gisselbrecht S, Gouilleux F. Cooperation between STAT-5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene. 2000;19:1164-1172.
36. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
37. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998;10:330-336.
38. Yam T, Yam A, Pece S, et al. Loss of PTEN expression leading to high akt activation in human multiple myelomas. Blood. 2000;96:3560-3568.
39. Sattler M, Verma S, Byrne CH, et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999;19:7473-7480.
40. Flint AJ, Gebbink MF, Franza BR Jr, Hill DE, Tonks NK. Multi-site phosphorylation of the protein tyrosine phosphatase, PTP1 B: identification of cell cycle regulated and phorbol ester stimulated sites of phosphorylation. EMBO J. 1993;12:1937-1946.
41. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B: possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J Biol Chem. 2000;275:4283-4289.
42. Wälchli S, Curchod M-L, Gobert RP, Arkinstall S, van Huijsduijnen RH. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor: a brute force approach based on "substrate-trapping" mutants. J Biol Chem. 2000;275:9792-9796.
43. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation, Cancer Res. 1996;56:3426-3430.
44. Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704- 31710.
45. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183:811-820.
46. Chatterjee-Kishore M, van den Akker F, Stark GR. Association of STATs with relatives and friends. Trends Cell Biol. 2000;10:106-111.
47. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
48. Gisselbrecht S. The CIS/SOCS proteins: a family of cytokine-inducible regulators of signaling. Eur Cytokine Netw. 1999;10:463-470.
49. Fujimoto NTM, Kishimoto T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci. 1999;24:394-398.
50. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Fit3 constitutively activates STAT-5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
51. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cb1 as a RING-type, E2-dependent ubiquitin-protein. Science. 1999;286:309-312.
52. Okabe S, Tauchi T, Morita H, Ohashi H, Yoshimura A, Ohyashiki K. Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquittn proteosome pathway. Exp Hematol. 1999;27:1542-1547.
53. Gorman DM, Itoh N, Jenkins NA, Gilbert DJ, Copeland NG, Miyajima A. Chromosomal localization and organization of the murine genes encoding the beta subunits (AIC2A and AIC2B) of the interleukin 3, granulocyte/macrophage colony-stimulating factor, and interleukin 5 receptors. J Biol Chem. 1992;267:15842-15848.
54. Hara T, Miyajima A. Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J. 1992;11:1875-1884.
55. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804-12809.